BofA raised the firm’s price target on Xenon Pharmaceuticals to $56 from $52 and keeps a Buy rating on the shares. The analyst updated the company’s model to reflect the recent equity raise. The firm believes ‘1101 is a “best-in-class seizure asset with blockbuster potential.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on XENE:
- Xenon Pharmaceuticals initiated with bullish view at Baird, here’s why
- Xenon Pharmaceuticals initiated with bullish view at Baird
- JPMorgan SMid cap biotech analyst to hold analyst/industry conference call
- Xenon Pharmaceuticals Announces Closing of $345.0 Million Upsized Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
- Xenon Pharmaceuticals Provides Updates on Neurology Pipeline Programs at the Annual Meeting of the American Epilepsy Society (AES 2023)
